CPGR, SimuGen Enter Into Biomarker Assay Pact | GenomeWeb

NEW YORK (GenomeWeb News) – South Africa's Centre for Proteomic and Genomic Research today said that it has entered into an agreement with SimuGen to develop biomarker assays for the prediction of toxicity of existing and new drug compounds.

SimuGen is a Malaysia-based pharmacogenomics firm working on novel dose-toxicity models for drug development customers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.